-
1
-
-
84869416865
-
Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5-HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study
-
Albany C, Brames MJ, Fausel C, et al (2012). Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5-HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol, 30, 3998-4003.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3998-4003
-
-
Albany, C.1
Brames, M.J.2
Fausel, C.3
-
2
-
-
0038047690
-
Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects
-
Blum RA, Majumdar A, McCrea J, et al (2003). Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther, 25, 1407-19.
-
(2003)
Clin Ther
, vol.25
, pp. 1407-1419
-
-
Blum, R.A.1
Majumdar, A.2
McCrea, J.3
-
3
-
-
79952860744
-
Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting
-
Bergstrom M, Hargreaves RJ, Burns HD, et al (2011). Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann N Y Acad Sci, 1222, 40-8.
-
(2011)
Ann N Y Acad Sci
, vol.1222
, pp. 40-48
-
-
Bergstrom, M.1
Hargreaves, R.J.2
Burns, H.D.3
-
4
-
-
0035868769
-
Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone
-
Campos D, Pereira JR, Reinhardt RR, et al (2001). Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol, 19, 1759-67.
-
(2001)
J Clin Oncol
, vol.19
, pp. 1759-1767
-
-
Campos, D.1
Pereira, J.R.2
Reinhardt, R.R.3
-
5
-
-
0035053631
-
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis
-
Cocquyt V, Van Belle S, Reinhardt RR, et al (2001). Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer, 37, 835-42.
-
(2001)
Eur J Cancer
, vol.37
, pp. 835-842
-
-
Cocquyt, V.1
Van Belle, S.2
Reinhardt, R.R.3
-
6
-
-
0037403701
-
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting
-
Chawla SP, Grunberg SM, Gralla RJ, et al (2003). Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer, 97, 2290-300.
-
(2003)
Cancer
, vol.97
, pp. 2290-2300
-
-
Chawla, S.P.1
Grunberg, S.M.2
Gralla, R.J.3
-
7
-
-
84897515769
-
Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin
-
Choi CH, Kim MK, Park JY, et al (2014). Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin. Support Care Cancer, 22, 1181-7.
-
(2014)
Support Care Cancer
, vol.22
, pp. 1181-1187
-
-
Choi, C.H.1
Kim, M.K.2
Park, J.Y.3
-
8
-
-
1642513757
-
The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase III clinical trials
-
de Wit R, Herrstedt J, Rapoport B, et al (2004). The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase III clinical trials. Eur J Cancer, 40, 403-10.
-
(2004)
Eur J Cancer
, vol.40
, pp. 403-410
-
-
de Wit, R.1
Herrstedt, J.2
Rapoport, B.3
-
9
-
-
84872584635
-
Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy
-
Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY (2013). Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy. Intern Med J, 43, 73-6.
-
(2013)
Intern Med J
, vol.43
, pp. 73-76
-
-
Gao, H.F.1
Liang, Y.2
Zhou, N.N.3
Zhang, D.S.4
Wu, H.Y.5
-
10
-
-
0347816226
-
Aprepitant Protocol 052 Study Group. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group
-
Hesketh PJ, Grunberg SM, Gralla RJ, et al (2003). Aprepitant Protocol 052 Study Group. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol, 21, 4112-9.
-
(2003)
J Clin Oncol
, vol.21
, pp. 4112-4119
-
-
Hesketh, P.J.1
Grunberg, S.M.2
Gralla, R.J.3
-
11
-
-
2342483811
-
Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant
-
Hargreaves R, Ferreira JC, Hughes D, et al (2004). Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry, 55, 1007-12.
-
(2004)
Biol Psychiatry
, vol.55
, pp. 1007-1012
-
-
Hargreaves, R.1
Ferreira, J.C.2
Hughes, D.3
-
12
-
-
33646412299
-
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response
-
Hesketh PJ, Grunberg SM, Herrstedt J, et al (2006). Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer, 14, 354-60.
-
(2006)
Support Care Cancer
, vol.14
, pp. 354-360
-
-
Hesketh, P.J.1
Grunberg, S.M.2
Herrstedt, J.3
-
13
-
-
79956158979
-
Negative impact of chemotherapy on breast cancer patients QOL-utility of antiemetic treatment guidelines and the role of race
-
Hassan BA, Yusoff ZB (2010). Negative impact of chemotherapy on breast cancer patients QOL-utility of antiemetic treatment guidelines and the role of race. Asian Pac J Cancer Prev, 11, 1523-7.
-
(2010)
Asian Pac J Cancer Prev
, vol.11
, pp. 1523-1527
-
-
Hassan, B.A.1
Yusoff, Z.B.2
-
14
-
-
77956458957
-
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy
-
Hesketh PJ, Aapro M, Street JC, Carides AD (2010). Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer, 18, 1171-7.
-
(2010)
Support Care Cancer
, vol.18
, pp. 1171-1177
-
-
Hesketh, P.J.1
Aapro, M.2
Street, J.C.3
Carides, A.D.4
-
15
-
-
84895878181
-
Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial
-
Hu Z, Cheng Y, Zhang H, et al (2014). Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial. Support Care Cancer, 22, 979-87.
-
(2014)
Support Care Cancer
, vol.22
, pp. 979-987
-
-
Hu, Z.1
Cheng, Y.2
Zhang, H.3
-
16
-
-
64449083250
-
Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy
-
Jordan K, Kinitz I, Voigt W, et al (2009). Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer, 45, 1184-7.
-
(2009)
Eur J Cancer
, vol.45
, pp. 1184-1187
-
-
Jordan, K.1
Kinitz, I.2
Voigt, W.3
-
17
-
-
84875152856
-
Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients
-
Janelsins MC, Tejani MA, Kamen C, et al (2013). Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother, 14, 757-66.
-
(2013)
Expert Opin Pharmacother
, vol.14
, pp. 757-766
-
-
Janelsins, M.C.1
Tejani, M.A.2
Kamen, C.3
-
18
-
-
84893430104
-
Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia
-
Keat CH, Ghani NA (2013). Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia. Asian Pac J Cancer Prev, 14, 7701-6.
-
(2013)
Asian Pac J Cancer Prev
, vol.14
, pp. 7701-7706
-
-
Keat, C.H.1
Ghani, N.A.2
-
19
-
-
33845900962
-
Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients
-
Loos WJ, de Wit R, Freedman SJ, et al (2007). Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol, 59, 407-12.
-
(2007)
Cancer Chemother Pharmacol
, vol.59
, pp. 407-412
-
-
Loos, W.J.1
de Wit, R.2
Freedman, S.J.3
-
20
-
-
0037757975
-
Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone
-
McCrea JB, Majumdar AK, Goldberg MR, et al (2003). Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther, 74, 17-24.
-
(2003)
Clin Pharmacol Ther
, vol.74
, pp. 17-24
-
-
McCrea, J.B.1
Majumdar, A.K.2
Goldberg, M.R.3
-
21
-
-
0033590464
-
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group
-
Navari RM, Reinhardt RR, Gralla RJ, et al (1999). Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med, 340, 190-5.
-
(1999)
N Engl J Med
, vol.340
, pp. 190-195
-
-
Navari, R.M.1
Reinhardt, R.R.2
Gralla, R.J.3
-
22
-
-
53149119534
-
Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting
-
Nakade S, Ohno T, Kitagawa J, et al (2008). Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol, 63, 75-83.
-
(2008)
Cancer Chemother Pharmacol
, vol.63
, pp. 75-83
-
-
Nakade, S.1
Ohno, T.2
Kitagawa, J.3
-
23
-
-
82855171513
-
Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial
-
Navari RM, Gray SE, Kerr AC (2011). Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol, 9, 188-95.
-
(2011)
J Support Oncol
, vol.9
, pp. 188-195
-
-
Navari, R.M.1
Gray, S.E.2
Kerr, A.C.3
-
24
-
-
84921773808
-
-
NCCN clinical Practice guidelines in oncology-antiemesis version I. 2014 (2014). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive.
-
(2014)
-
-
-
25
-
-
84879161805
-
Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy
-
Olver IN, Grimison P, Chatfield M, et al (2013). Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Support Care Cancer, 21, 1561-8.
-
(2013)
Support Care Cancer
, vol.21
, pp. 1561-1568
-
-
Olver, I.N.1
Grimison, P.2
Chatfield, M.3
-
26
-
-
0038728753
-
Aprepitant protocol 054 study group.cancer. addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. results from a randomized, double-blind, placebo-controlled trial in Latin America
-
Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al (2003). Aprepitant protocol 054 study group.cancer. addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer, 97, 3090-8.
-
(2003)
Cancer
, vol.97
, pp. 3090-3098
-
-
Poli-Bigelli, S.1
Rodrigues-Pereira, J.2
Carides, A.D.3
-
27
-
-
77952480785
-
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study
-
Rapoport BL, Jordan K, Boice JA, et al (2010). Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer, 18, 423-31.
-
(2010)
Support Care Cancer
, vol.18
, pp. 423-431
-
-
Rapoport, B.L.1
Jordan, K.2
Boice, J.A.3
-
28
-
-
70649090118
-
Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function
-
Rojas C, Thomas AG, Alt J, et al (2012). Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol, 626, 193-9.
-
(2012)
Eur J Pharmacol
, vol.626
, pp. 193-199
-
-
Rojas, C.1
Thomas, A.G.2
Alt, J.3
-
29
-
-
84892868999
-
Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis
-
Rojas C, Raje M, Tsukamoto T, Slusher BS (2014). Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol, 722, 26-37.
-
(2014)
Eur J Pharmacol
, vol.722
, pp. 26-37
-
-
Rojas, C.1
Raje, M.2
Tsukamoto, T.3
Slusher, B.S.4
-
30
-
-
84892805731
-
Cancer statistics, 2014
-
Siegel R, Ma J, Zou Z, et al (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29.
-
(2014)
CA Cancer J Clin
, vol.64
, pp. 9-29
-
-
Siegel, R.1
Ma, J.2
Zou, Z.3
-
31
-
-
77958559550
-
Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin
-
Takahashi T, Hoshi E, Takagi M, et al (2010). Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci, 101, 2455-61.
-
(2010)
Cancer Sci
, vol.101
, pp. 2455-2461
-
-
Takahashi, T.1
Hoshi, E.2
Takagi, M.3
-
32
-
-
79959331489
-
Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients
-
Takahashi T, Nakamura Y, Tsuya A, et al (2011). Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients. Cancer Chemother Pharmacol, 68, 653-9.
-
(2011)
Cancer Chemother Pharmacol
, vol.68
, pp. 653-659
-
-
Takahashi, T.1
Nakamura, Y.2
Tsuya, A.3
-
33
-
-
84873695492
-
Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy
-
Uchino J, Hirano R, Tashiro N, et al (2012). Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy. Asian Pac J Cancer Prev, 13, 4187-90.
-
(2012)
Asian Pac J Cancer Prev
, vol.13
, pp. 4187-4190
-
-
Uchino, J.1
Hirano, R.2
Tashiro, N.3
-
34
-
-
0036604223
-
Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758, 298 and MK-869
-
Van Belle S, Lichinitser MR, Navari RM, et al (2002). Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758, 298 and MK-869. Cancer, 94, 3032-41.
-
(2002)
Cancer
, vol.94
, pp. 3032-3041
-
-
Van Belle, S.1
Lichinitser, M.R.2
Navari, R.M.3
-
35
-
-
21044434743
-
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy
-
Warr DG, Hesketh PJ, Gralla RJ, et al (2005). Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol, 23, 2822-30.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2822-2830
-
-
Warr, D.G.1
Hesketh, P.J.2
Gralla, R.J.3
-
36
-
-
58549114412
-
A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
-
Yeo W, Mo FK, Suen JJ, et al (2009). A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat, 113, 529-35.
-
(2009)
Breast Cancer Res Treat
, vol.113
, pp. 529-535
-
-
Yeo, W.1
Mo, F.K.2
Suen, J.J.3
|